Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18263840 | 0.84 | MIF (0.59) | KIF11HTTMAPTKMT2ACYP2C19 | |
| SCHEMBL27979602 | 0.82 | MAPT (0.48) | KIF11HTTMAPTKMT2ACYP2C19 | |
| SCHEMBL503257 | 0.81 | MIF (0.65) | KIF11MAPTKMT2ACYP2C19HIF1A | |
| SCHEMBL10483830 | 0.80 | MAPT (0.47) | KIF11HTTMAPTKMT2ACYP2C19 | |
| SCHEMBL7381704 | 0.80 | HTT (0.47) | KIF11HTTMAPTKMT2ACYP2C19 | |
| SCHEMBL6376761 | 0.79 | PTPN1 (0.44) | HTTMAPTKMT2ACYP2C19HIF1A | |
| SCHEMBL20546665 | 0.79 | MIF (0.63) | KIF11MAPTKMT2ACYP2C19HIF1A | |
| SCHEMBL11124539 | 0.78 | CYP2C19 (0.44) | KIF11HTTMAPTKMT2ACYP2C19 | |
| SCHEMBL7776492 | 0.78 | MAPT (0.45) | KIF11HTTMAPTKMT2ACYP2C19 | |
| SCHEMBL16212235 | 0.78 | PTPN1 (0.47) | HTTMAPTKMT2ACYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119246718-A | Chiral analysis method of semaglutin series intermediates | 杭州澳赛诺医药技术有限公司 | 2025-01-03 | — | — | CN | claimed |
| US-20250051477-A1 | ANTI-MUSK ANTIBODIES FOR USE IN TREATING NEUROMUSCULAR DISORDERS | argenx BV (BE) | 2025-02-13 | — | — | US | disclosed |
| CN-119246718-A | Chiral analysis method of semaglutin series intermediates | 杭州澳赛诺医药技术有限公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-4469085-A2 | ANTI-MUSK ANTIBODIES FOR USE IN TREATING NEUROMUSCULAR DISORDERS | Argenx BV (BE) | 2024-12-04 | — | — | EP | disclosed |
| US-20240374563-A1 | ANTICHOLINERGIC COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | UNIVERSITY OF MONTRÉAL (CA) | 2024-11-14 | — | — | US | disclosed |
| WO-2023141721-A1 | ANTICHOLINERGIC COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | UNIVERSITY OF MONTRÉAL (CA) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147489-A2 | ANTI-MUSK ANTIBODIES FOR USE IN TREATING NEUROMUSCULAR DISORDERS | argenx BV (BE) | 2023-08-03 | — | — | WO | disclosed |
| CN-116444449-A | Preparation method of 3- (chloromethyl) -1-methyl-1H- [1,2,4] -triazole | 怀化宝华生物科技有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20160158375-A1 | DIPEPTIDE LINKED MEDICINAL AGENTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-06-09 | — | — | US | disclosed |
| EP-2739616-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES AS JAK INHIBITORS | Almirall, S.A. (ES) | 2014-06-11 | — | — | EP | disclosed |
| US-6509369-B2 | Triphenylpropanamide compounds; useful in treating inflammations but which do not demonstrate side effects associated with other anti-inflammatory treatments such as glucocorticoids | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20020103217-A1 | Anti-inflammatory compounds | SCOTT MALCOLM K (US) | 2002-08-01 | — | — | US | disclosed |
| EP-1213281-A1 | NOVEL AMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-06-12 | — | — | EP | disclosed |
| EP-0966430-B1 | ANTI-INFLAMMATORY COMPOUNDS | ORTHO MCNEIL PHARM INC (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6372779-B1 | ANTHRACENE DERIVATIVES WITH CARBAMOYL GROUPS, AMIDO GROUPS, UREA GROUPS AND SULFONAMIDE GROUPS | ORTHO PHARMACEUTICAL CORPORATION | 2002-04-16 | — | — | US | disclosed |
| EP-1158971-A1 | GARDOS CHANNEL ANTAGONISTS | Icagen, Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6288122-B1 | A TRIPHENYL ACETAMIDE | ICAGEN, INC. | 2001-09-11 | — | — | US | disclosed |
| WO-2000050026-A1 | GARDOS CHANNEL ANTAGONISTS | ICAGEN, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-0966430-A1 | ANTI-INFLAMMATORY COMPOUNDS | Ortho-Mcneil Pharmaceutical Corp. (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999033786-A1 | ANTI-INFLAMMATORY COMPOUNDS | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158375-A1 | DIPEPTIDE LINKED MEDICINAL AGENTS | DNPEP, PEPD, CNDP2 | KIF11 3916/4885HTT 2595/4885MAPT 2884/4885 |
| US-20240374563-A1 | ANTICHOLINERGIC COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | CHRNA6, CHRNA5, CHRNA10 | KIF11 1318/4885HTT 269/4885MAPT 375/4885 |
| US-20250051477-A1 | ANTI-MUSK ANTIBODIES FOR USE IN TREATING NEUROMUSCULAR DISORDERS | MUSK, ACHE, CHRM3 | KIF11 983/4885HTT 1318/4885MAPT 378/4885 |
| US-20020103217-A1 | Anti-inflammatory compounds | TNF, PTGES, PTGES2 | KIF11 4772/4885HTT 1315/4885MAPT 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.